Merck is licensing alimatravir before Phase 3 ends. Can a monthly HIV pill beat the access clock?
Merck’s alimatravir access plan covers 129 countries, but Phase 3 efficacy, pricing and regulatory execution will decide its HIV PrEP impact.
Pharma & Biotech
Pharma & Biotech
Gilead’s Trodelvy cleared a key EU hurdle, but can it really replace chemotherapy in first-line TNBC?
CHMP backs Trodelvy plus Keytruda for first-line PD-L1-positive metastatic TNBC, moving Gilead closer to an expanded EU label.
Pharma & Biotech
Scancell secures path to $89m financing through Neuphoria Therapeutics merger
Scancell will acquire Neuphoria Therapeutics and pursue up to $89 million to fund the Phase 3 iSCIB1+ melanoma trial through 2028.
Pharma & Biotech
Can one HIV pill a week replace daily therapy? Gilead and Merck’s Phase 3 data raise the stakes
Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.
Pharma & Biotech
Why Kelun-Biotech’s latest sac-TMT Phase III result could matter more than the headline suggests
Kelun-Biotech reports improved Phase III PFS with sac-TMT plus pembrolizumab, while survival and detailed safety data remain pending.
Pharma & Biotech
Multikine is back in Phase 3, but can CEL-SCI turn a striking subgroup signal into approval?
CEL-SCI launches a 212-patient Multikine Phase 3 study, but subgroup validation, funding and regulatory execution remain decisive.
Pharma & Biotech
Can Merck’s IDVYNSO agreement widen HIV treatment access across state programmes?
See how Merck’s IDVYNSO ADAP agreement could widen HIV treatment access while pricing, formularies and clinical limits shape uptake.
Pharma & Biotech
Merck and Gilead secure FDA approval for a new ADC-immunotherapy backbone in advanced TNBC
The new regimen replaces conventional chemotherapy with a Trop-2-directed antibody-drug conjugate while retaining PD-1 blockade, offering longer disease control but leaving overall survival, sequencing and cost questions unresolved.
Pharma & Biotech
Gilead expands Trodelvy into first-line metastatic TNBC, but survival questions remain unresolved
The decision gives clinicians a Trodelvy-based option for patients who cannot receive checkpoint inhibitors and a Trodelvy plus Keytruda regimen for PD-L1-positive disease. The immediate clinical impact is substantial, although immature overall-survival data, toxicity management and treatment cost will influence how rapidly the new pathways displace chemotherapy.
Pharma & Biotech
Merck moves Welireg earlier as FDA clears Keytruda combinations in high-risk ccRCC
Find out how Merck’s Keytruda and Welireg approval could reshape adjuvant clear cell renal cell carcinoma treatment.